Control of inflammation and periodontitis.
Van Dyke
Thomas E
TE
Department of Periodontology and Oral Biology, Goldman School of Dental Medicine, Boston University, Boston, MA, USA.
D016301:Alveolar Bone Loss / Q000188:drug therapy; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D018441:Biofilms; D001861:Bone Regeneration / Q000187:drug effects; D004198:Disease Susceptibility; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism*; D044045:Lipoxins / Q000502:physiology*; D010518:Periodontitis / Q000188:drug therapy* / Q000378:metabolism* / Q000382:microbiology
D000893:Anti-Inflammatory Agents; D044045:Lipoxins; D015118:Eicosapentaenoic Acid; C499823:5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid; D001241:Aspirin